Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Read moreFaron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Read moreFaron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
Read moreFaron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
Read moreFaron Pharmaceuticals Applies For Nasdaq First North Growth Listing
Read moreUK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
Read moreFaron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
Read moreLONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
Read moreFaron Pharmaceuticals Unable To Explain Significant Shares Price Surge
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.
Read moreFaron Pharmaceuticals To Test New Lower Dose In Clevegen Study
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim results in relation to the active pharmaceutical ingredient (API) manufacturing process for 'Traumakine', Rentschler Biopharma has sent Faron a letter in which it terminated the agreement concerning the API manufacturing.
Read moreManufacturer Ends Traumakine Agreement With Faron Pharmaceuticals
Read more(Alliance News) - Faron Pharmaceuticals Oy on Monday said its loss narrowed considerably in the first half of 2019, after it cut back on research & development spending and opted to end a firm
Read moreTuesday 17 September JTCHalf Year ResultsStafflineHalf Year GroupHalf Year Year
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has received valid acceptances and excess applications from qualifying shareholders for a total of 859,513 open offer shares, raising gross proceeds of around €1.01m (£0.92m) at the issue price of 106p per share and at the euro issue price of 119 cents per share, it announced on Tuesday.
Read more